Article Text

Simvastatin was cost effective across a broad range of risk and age groups

Statistics from

 Q Is 40 mg/day of generic simvastatin continued for life cost effective in patients of different ages with differing risks of vascular disease?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Cardiology ★★★★★★☆ Internal medicine ★★★★★☆☆


Embedded ImageDesign:

cost effectiveness study using a Markov model developed from a randomised {allocation concealed*}, blinded {patients, clinicians, data collectors, and outcome assessors},* placebo controlled trial with mean 5 year follow up (Heart Protection Study [HPS]).

Embedded ImageSetting:

69 UK hospitals.

Embedded ImagePatients:

20 536 patients 40–80 years of age with total cholesterol concentrations ⩾3.5 mmol/l (135 mg/dl) and history of coronary disease, cerebrovascular disease, other occlusive arterial disease, diabetes mellitus, or treated hypertension (in men ⩾65 y). Within the HPS, patients were divided into 5 similar sized groups by estimated 5 year risk of a major vascular event (12%, …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Other articles noted
    BMJ Publishing Group Ltd
  • Glossary
    BMJ Publishing Group Ltd